10-Q: Silence Therapeutics Reports Q2 2026 Results, Faces Funding Needs

Silence Therapeutics plc filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and outlining the need for future capital raises.

Summary

• Silence Therapeutics plc filed its quarterly report for the period ended June 30, 2026.
• The company reported a net loss of $12.3 million for the three months ended June 30, 2026, and $27.2 million for the six months ended June 30, 2026.
• As of June 30, 2026, the company had cash and cash equivalents of $72.1 million.
• Management believes current cash is sufficient to fund operations into 2028, but additional funding will be required for clinical development.
• The company is exploring various funding options including public or private financings, debt financing, or collaboration agreements.
• Revenue for the three months ended June 30, 2026, was nil, a decrease from $0.2 million in the prior year period.
• Revenue for the six months ended June 30, 2026, was $0.4 million, similar to the prior year period.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant net losses, ongoing operational deficits, and the explicit statement that additional funding will be required to continue operations, despite a cash runway into 2028.

Positives

• The company's cash and cash equivalents of $72.1 million as of June 30, 2026, are believed to be sufficient to fund operations into 2028.
• Divesiran (SLN124) completed patient dosing in the Phase 2 SANRECO trial, with topline results anticipated in August 2026.
• Zerlasiran (SLN360) has received positive regulatory feedback on its Phase 3 cardiovascular outcomes study design.
• SLN548, SLN365, and SLN098 are advancing with preclinical data and potential IND filings targeted for 2027.
• The company received $14.2 million related to the receipt of the 2024 claim for past research and development tax credits.

Negatives

• The company incurred a net loss of $12.3 million for the three months ended June 30, 2026, and $27.2 million for the six months ended June 30, 2026.
• Revenue for the three months ended June 30, 2026, was nil, a decrease from $0.2 million in the prior year period.
• Research and development costs decreased significantly due to the completion of Phase 3 readiness for zerlasiran in 2025 and reduced headcount.
• AstraZeneca notified Silence that they will not pursue further development of SLN312 beyond Phase 1, though Silence will regain global rights.
• The company has a history of recurring losses and expects to continue incurring operating losses for the foreseeable future.
• Additional funding will be required to fund operating expenses and capital expenditure requirements related to clinical development activities.

Risks

• The company has incurred recurring losses since inception and expects to continue incurring operating losses for the foreseeable future.
• The company will need to raise additional funding to fund its operating expenses and capital expenditure requirements in relation to its clinical development activities.
• The inability to obtain future funding could impact the Group's financial condition and ability to pursue its business strategies, including being required to delay, reduce or eliminate some of its research and development programs, or being unable to continue operations or unable to continue as a going concern.
• The successful development of product candidates is highly uncertain, and product candidates in later stages of clinical development generally have higher development costs.
• Future changes to the U.K. R&D tax credit regime may mean the company no longer qualifies or may have a material impact on the extent to which it can make claims.
• The company is subject to risks associated with clinical trial enrollment rates, patient drop-out rates, and competition with other drug development companies.
• AstraZeneca has the right to terminate the collaboration agreement on a target-by-target basis or in its entirety.

Future Outlook

The company believes its current cash and cash equivalents are sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2028. However, additional funding will be required to support clinical development activities, and the company may seek this through public or private financings, debt financing, or collaboration agreements. Future milestone payments from collaborations could extend operational funding.

Management Comments

• Based on this evaluation, the Group believes that its current cash and cash equivalents as of June 30, 2026 are sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2028.
• The Group will need to raise additional funding to fund its operating expenses and capital expenditure requirements in relation to its clinical development activities.
• The Group may seek additional funding through public or private financings, debt financing or collaboration agreements.
• Specifically, the Group may receive future milestone payments from collaboration agreements which will extend the ability to fund operations.
• However, these future milestone payments are dependent on achievement of certain development or regulatory objectives that may not occur.
• The inability to obtain future funding could impact the Groups financial condition and ability to pursue its business strategies, including being required to delay, reduce or eliminate some of its research and development programs, or being unable to continue operations or unable to continue as a going concern.

Industry Context

StockSavvy.ai notes that Silence Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on RNA therapeutics. The company's reliance on collaborations and the need for significant future funding are common themes in this industry, particularly for companies advancing drug candidates through clinical trials.

Comparison to Industry Standards

• The company's net loss of $27.2 million for the six months ended June 30, 2026, is substantial, reflecting the high costs associated with drug development in the biotechnology sector.
• The cash runway into 2028, while positive, is contingent on future funding, a common challenge for pre-revenue biotech firms.
• The decrease in R&D spending compared to the prior year, particularly in contracted development costs for zerlasiran, suggests a shift in focus or completion of specific development phases, which is typical as programs mature or partnerships evolve.
• The decision by AstraZeneca not to pursue further development of SLN312 beyond Phase 1, while a setback for that specific asset, is a common occurrence in drug development partnerships where strategic priorities can shift.

Legal Proceedings

• The company is not party to any material legal proceedings at this time.

Related Party Transactions

• None disclosed in the filing.

Stakeholder Impact

• Shareholders may be concerned about the continued net losses and the need for future capital raises, which could dilute existing ownership.
• Employees may face uncertainty due to the company's ongoing need for funding and potential restructuring or reduction in R&D activities.
• Creditors and suppliers may be impacted if the company faces significant financial distress or is unable to secure future funding.
• Partners like AstraZeneca have specific rights to terminate agreements, impacting the strategic direction and potential value realization for stakeholders.

Next Steps

• Anticipate topline results from the Phase 2 SANRECO trial for divesiran in August 2026.
• Evaluate plans for further clinical development of SLN312 after regaining global rights.
• Seek a third-party partner for potential Phase 3 development and commercialization of zerlasiran.
• Seek a third-party partner to initiate clinical development for SLN548.
• Potential IND filing for SLN365 in 2027.
• Potential IND filing for SLN098 in 2027.

Key Dates

Recommendation

The company shows promising pipeline assets with positive preclinical and early-stage clinical data, particularly Divesiran and Zerlasiran. However, the significant and ongoing net losses, coupled with the explicit need for future capital raises, introduce substantial financial risk. While the cash runway extends into 2028, the dependency on external funding for continued development warrants a cautious approach. A 'hold' recommendation reflects the balance between pipeline potential and financial uncertainty.

Keywords

RNA therapeutics, siRNA, Divesiran, Zerlasiran, AstraZeneca collaboration, clinical trials, biotechnology, drug development